Important Takeaways:

• Self-copying RNA vaccine wins first full approval: what’s next?
• The endorsement last week by Japanese authorities of a jab against SARS-CoV-2 constructed using a form of RNA that can make copies of itself inside cells — the first ‘self-amplifying’ RNA (saRNA) granted full regulatory approval anywhere in the world — marks a pivotal advance.
• Researchers have been trying to make saRNA vaccines a reality for more than 20 years.
• “saRNA is a totally different beast.”
• With approval for ARCT-154 secured in Japan, its developers are now seeking authorization in Europe; a regulatory decision is expected next year.

Read the original article by clicking here.